This resulted in the phenotypic transition of VSMCs from a contractile to a synthetic state and increased plaque area by 47.4% and heightened plaque instability, indicating that targeting Fam172a or KLF4 using gene therapy may offer a new therapeutic approach for atherosclerosis [105]. This evidence concerns the gene KLF4 and atherosclerosis.